Human cancer studies on exposure to pentachlorophenol (PCP): Differentiating potential cancer effects of PCP exposure from effects due to occupational co-exposures or PCP contaminants

April 11, 2013, 12:30 to 5:00 PM

Draft AGENDA

Welcome and Introductions

Presentations (20 to 30 minutes each)
Each presentation will be followed by short question and answer period (~15 minutes) specific for the presentation.

Presentation 1. *Overview of occupational exposures to pentachlorophenol: Components, contaminants, and common co-exposures*
Kevin Dunn, M.S., National Institute for Occupational Safety and Health (NIOSH)

Presentation 2. *Occupational exposure to PCP and other agents: Issues to consider in evaluating human epidemiology studies*
Avima Ruder, Ph.D., NIOSH

Presentation 3. *Biomonitoring and epidemiologic studies of PCP producers*
Jim Collins, Ph.D., The Dow Chemical Company

Presentation 4. *Epidemiologic studies of PCP users*
Paul Demers, Ph.D., Occupational Cancer Research Centre, Cancer Care Ontario; Professor, Dalla Lana School of Public Health, University of Toronto

Discussion
General discussion across presentations. Discussion is open to the public, speakers, technical advisors, and NTP staff.

Closing Remarks